Friday 26 Apr, 2024 03:24 AM
Site map | Locate Us | Login
   IndusInd Bank Q4 PAT rises 15% YoY to Rs 2,347 cr    Tech Mahindra Q4 PAT climbs 29% QoQ; declares dividend of Rs 28/ share    Laurus Labs slides after Q4 PAT tumbles 26% YoY to 76 cr    ACC records four-fold jump in Q4 PAT to Rs 945 cr    Vedanta PAT slides 27% YoY to Rs 1,369 cr in Q4 FY24    Inox Wind hits record high as board OKs 3:1 bonus issue    Glenmark Life drops after Q4 PAT slides 33% YoY to Rs 98 cr; Generic API biz down 8% YoY    Kotak Mahindra Bank Ltd leads losers in 'A' group    H G Infra soars on entry in energy, green hydrogen segment    Avantel Ltd leads losers in 'B' group    Tata Tele slides as net loss widens to Rs 309 cr in Q4    AU SFB slides after Q4 PAT drops 13% YoY to Rs 371 cr    Volumes jump at Sun Pharma Advanced Research Company Ltd counter    Consumer goods shares slide    Consumer Durables shares fall 
Saravan Stocks
       
IPO Synopsis
Glenmark Life Sciences Ltd
Registered Office: Plot No. 170-172 Chandramouli,Industrial Est.Mohol Bazarpeth, Solapur - 413213, Maharashtra, India.
Phone : 91-2189-234456/234246   Fax:
Email :  complianceofficer@glenmarklifesciences.com  
Website :  www.glenmarklifesciences.com
Initial public offer of 21,022,222 equity shares of face value of Rs. 2 each ("equity shares") of Glenmark Life Sciences Limited ("Company" or "Issuer") for cash at a price of Rs. 720 per equity share (including a share premium of Rs. 718 per equity share) aggregating to Rs. 1513.60 crores (the "offer") comprising a fresh issue of 14,722,222 equity shares aggregating to Rs. 1060 crores (the "fresh issue") and an offer for sale of up to 6,300,000 equity shares by Glenmark Pharmaceuticals Limited ("Promoter Selling Shareholder") and such equity shares, The "offered shares") aggregating to Rs. 453.60 crores (The "offer for sale"). The offer shall constitute 17.16% of the post-offer paid-up equity share capital of the company. The face value of equity shares is Rs. 2 each. Offer Price : Rs. 720 per Equity Share of face value of Rs. 2 each. Anchor Investor offer price: Rs. 720 per Equity share. The Offer Price is 360 times the face value.
Issue Money Payable On
Opens On Closes On Application Allotment
27-Jul-21 29-Jul-21 720.00-0.00 0.00-0.00
Minimum Application for shares in Nos : 20   Further Multiples of : 20
  Rs Cr Lead Managers to the Issue
Project Cost 1060.00 BOB Capital Markets Ltd
Project Financed through Current Offer 1513.60  
Post Issue Equity Share Capital 24.51  
Issue Price 720.00  
Projects
Payment of outstanding purchase consideration to the promoter for the spin-off of the API business from the promoter into the company pursuant to the Business Purchase agreement Funding capital expenditure requirements
General corporate purposes
Promoted By
Glenmark Pharmaceuticals Ltd
Listing At
BSE
NSE
Registrar to the Issue
No Data Available
   Attention Investors : Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day........issued in the interest of investors.
   Attention Investors : Prevent unauthorised transactions in your account Update your mobile numbers/email IDs with your stock brokers / Depository Participant. Receive information of your transactions directly from Exchange / Depositories on your mobile / email at the end of the day .... Issued in the interest of Investors.
   Attention Investors : KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
   Attention Investors : No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
Email ID: info@ssplwealth.com       Customers grievances : grievances@ssplwealth.com     Compliance officer : Mr.R Udayakumar , compliance@ssplwealth.com,  Mobile No: 7305522205
Hit Count : 32138319
SEBI Regn.Nos : NSE/BSE-INZ000192638 | CDSL : IN-DP-262-2016
Member IDs : NSE : 11221 | BSE : 6292 | CDSL : 12045000 | MCX : 56990 | AMFI Regn.No : 2662
Designed , Developed & Content provided by CMOTS INFOTECH.(ISO 9001:2015 certified) © Copyright 2011 All Rights Reserved. SSPL WEALTH Pvt. Ltd